Scienza e Tecnologia
ThinkCyte expands product portfolio to drive innovation in drug discovery and disease research.
"The expansion of our product portfolio reflects our unwavering commitment to advancing life science research." said Waichiro Katsuda, Chief Executive Officer at ThinkCyte. "By introducing innovative solutions that address the evolving needs of scientists worldwide, we're not just adding products—we're providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives."
More information about the VisionCyte platform can be found by visiting the ThinkCyte booth (# ) at SLAS 2025 or by visiting thinkcyte.com/visioncyte .
ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company pioneered Ghost Cytometry™, a proprietary AI-based, label-free cell analysis and sorting technology and partners with major global biopharmaceutical companies and leading academic research institutes to drive pioneering research. For more information, please visit www.thinkcyte.com .
Photo - https://mma.prnewswire.com/media/2605950/VisionCyte.jpg
Logo - https://mma.prnewswire.com/media/2605983/ThinkCyte_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/thinkcyte-expands-product-portfolio-to-drive-innovation-in-drug-discovery-and-disease-research-302360367.html